Tri Locum Partners LP Iveric Bio, Inc. Transaction History

Tri Locum Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $2.55 Million - $3.35 Million	-136,368 Reduced 56.1%	106,711 $2.6 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $904,789 - $1.26 Million	52,482 Added 27.54%	243,079 $5.2 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $1.79 Million - $3.54 Million	190,597 New	190,597 $3.42 Million
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $4.6 Million - $9.53 Million	-504,371 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $6.13 Million - $8.49 Million	504,371 New	504,371 $8.49 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $5.22 Million - $7.09 Million	-377,708 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $1.99 Million - $4.92 Million	280,888 Added 290.11%	377,708 $6.13 Million
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $550,905 - $694,199	96,820 New	96,820 $611,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.